Action Harbor Multi asset Explo...

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

22,1875

Prix Achat

Prix Vente

Volume échangé

22,17 Fourchette du Jour 22,17

20,9058 Plage de 52 semaines 24,39

Clôture Veille

22,3282

Ouverture

22,17

Dernière Transaction

100

22.1875

Dernière heure de transaction

00:30:00

Volume moyen (3 m)

805

Volume financier

VWAP

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.0769	-0.34539444135	22.2644	22.4	22.1875	5	22.29334762	SP
4	-0.9925	-4.28170836928	23.18	24.39	20.9058	2174	21.02282882	SP
12	-1.165	-4.98875923349	23.3525	24.39	20.9058	805	21.31470127	SP
26	-1.3775	-5.84553363038	23.565	24.39	20.9058	457	21.69221739	SP
52	0.9762	4.60226388764	21.2113	24.39	20.9058	376	22.03678617	SP
156	2.0475	10.1663356504	20.14	24.39	18.9015	665	20.8432415	SP
260	2.0475	10.1663356504	20.14	24.39	18.9015	665	20.8432415	SP

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Harbor Multi asset Explorer ETF (MAPP)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

MAPP Dernières nouvelles

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Harbor Multi asset Explorer ETF (MAPP) Cours

Harbor Multi asset Explorer ETF (MAPP)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

MAPP Dernières nouvelles

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités